Private company

MYMETICS CORP

American biological products company based in Epalinges, active since 19962

In its 2023 annual report the company says: “We are a vaccine company and are focused on the research and development of next generation vaccines for infectious and life disabling diseases. Our core technology and expertise lays in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens and if required, adjuvants.”34

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersEpalinges, Switzerland2
  • Incorporated inDE3
  • Business addressEuropean Executive Office, 4, Route De La Corniche, Epalinges, V8 Ch-10663
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI529900KG1SF2ROQHCL852
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o The Corporation Trust Company, Corporation Trust Center 1209 Orange Street, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 26634312

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2022

-169.7%Operating margin4
139.1%Revenue growth, 20224

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Other costs100¢1.0M EUR

Out of 1.0M EUR in revenue.4

Financial statements

Revenue567841.0M EUR in 2022−18% since 2016
0500.0K EUR1.0M EUR1.5M EUR2.0M EUR2016: 1.3M EUR1.3M EUR20162017: 1.5M EUR1.5M EUR2017+21%2018: 967.0K EUR967.0K EUR2018−36%2019: 653.0K EUR653.0K EUR2019−32%2020: 668.0K EUR668.0K EUR2020+2%2021: 430.0K EUR430.0K EUR2021−36%2022: 1.0M EUR1.0M EUR2022+139%
Operating income56784-1.7M EUR in 2022−49% since 2016
-4.0M EUR-3.0M EUR-2.0M EUR-1.0M EUR02016: -3.4M EUR-3.4M EUR20162017: -1.5M EUR-1.5M EUR2017−56%2018: -1.5M EUR-1.5M EUR2018+0%2019: -1.4M EUR-1.4M EUR2019−6%2020: -1.6M EUR-1.6M EUR2020+14%2021: -1.6M EUR-1.6M EUR2021+2%2022: -1.7M EUR-1.7M EUR2022+6%
Net income9-4.7M EUR in 2021+14% since 2020
-6.0M EUR-4.0M EUR-2.0M EUR02020: -4.2M EUR-4.2M EUR20202021: -4.7M EUR-4.7M EUR2021+14%
Fiscal year2016201720182019202020212022
Revenue1.3M EUR51.5M EUR6967.0K EUR7653.0K EUR8668.0K EUR8430.0K EUR41.0M EUR4
Operating expenses2.1M EUR42.8M EUR4
Operating income-3.4M EUR5-1.5M EUR6-1.5M EUR7-1.4M EUR8-1.6M EUR8-1.6M EUR4-1.7M EUR4
Income before tax-4.7M EUR4-4.8M EUR4
Income tax-11.0K EUR55.0K EUR619.0K EUR722.0K EUR925.0K EUR90 EUR40 EUR4
Net income-$4.2M9-$4.7M9
Earnings per share-$0.029
Shares (weighted, basic)303.8B shares4303.8B shares4

Compare MYMETICS CORP with another company

What it owns

What MYMETICS CORP reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation475.0K EUR4 Dec 31, 2022473.0K EUR4 Dec 31, 2021+0.4%
Property and equipment, net$39.0K9 Dec 31, 2021$48.0K9 Dec 31, 2020−18.8%
Operating-lease assets (leased space)$239.0K9 Dec 31, 2021$128.0K9 Dec 31, 2020+86.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$6.7M9 Dec 31, 2021$6.7M9 Dec 31, 20200%

Leadership

Who has led MYMETICS CORP, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Christian Rochet2007
  2. Jacques Francois Martin2010
  3. Grant Pickering2012
  4. Ronald Hugo Gerard Kempers2014–2023

President

  1. Christian Rochet2007
  2. Grant Pickering2012
  3. Ronald Hugo Gerard Kempers2014–2023

Chief financial officer

  1. Ernst Luebke2007
  2. Ronald Hugo Gerard Kempers2010–2023
2010201520202025
Board members and other officers (10)

Former names

  • ICHOR CORPNov 14, 1997 to Jun 29, 20013
  • PDG REMEDIATION INCJun 14, 1996 to Mar 3, 19973

Timeline

  1. Dec 28, 20238-K Bylaws or fiscal year changed26
  2. Oct 24, 20238-K Other events27
  3. Oct 11, 20238-K Shareholder vote; Other events28
  4. Jul 31, 20238-K Other events29
  5. Feb 27, 20238-K Other events30
  6. Feb 8, 20238-K Other events31
  7. Jan 17, 20238-K Executive or director change32
  8. Dec 28, 20228-K Executive or director change33
  9. Jan 8, 2014New chief executive Ronald Hugo Gerard Kempers becomes CEO13
  10. Apr 5, 2012New chief executive Grant Pickering becomes CEO14
  11. Jul 14, 2010New chief executive Jacques Francois Martin becomes CEO15
  12. Jun 22, 2007New chief executive Christian Rochet becomes CEO16
  13. Sep 16, 1996Founded MYMETICS CORP is founded2

Filings

34 filings to the SEC since October 2021: 3 annual reports, 7 quarterly reports, 8 major events, 3 insider forms, 13 other. The latest 20:

  1. Jan 2, 202415-12G EDGAR
  2. Dec 28, 20238-K EDGAR
  3. Dec 12, 2023EFFECT EDGAR
  4. Dec 8, 2023POS AM EDGAR
  5. Dec 8, 2023S-8 POS EDGAR
  6. Dec 8, 2023POS AM EDGAR
  7. Dec 8, 2023S-8 POS EDGAR
  8. Nov 20, 202310-Q EDGAR
  9. Nov 15, 2023NT 10-Q EDGAR
  10. Oct 27, 2023DEF 14C EDGAR
  11. Oct 27, 2023SC 13E3/A EDGAR
  12. Oct 24, 20238-K EDGAR
  13. Oct 17, 2023SC 13E3 EDGAR
  14. Oct 16, 2023PRE 14C EDGAR
  15. Oct 11, 20238-K EDGAR
  16. Aug 18, 202310-Q EDGAR
  17. Aug 15, 2023NT 10-Q EDGAR
  18. Jul 31, 20238-K EDGAR
  19. May 15, 202310-Q EDGAR
  20. Apr 11, 202310-K EDGAR

The 34 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How MYMETICS CORP is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMYMETICS CORP1
  • CIK0000927761
  • Employer ID (EIN)25-17418491
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressEuropean Executive Office, 4, Route De La Corniche, Epalinges, V8 CH-10661
  • Phone011-41-21-653-45-351
  • Shares outstanding303,757,622 as of Nov 20, 202312
  • Public float$4.6M as of Dec 31, 20224
  • On EDGAR sinceMay 29, 19961
  • Filings348 in all: 10-Q (84), 8-K (77), 10-K (22), SC 13D/A (19), 3 (16), 8-K/A (15), SC 13D (12), 4 (11)1
    All 38 form types

    NT 10-Q (9), DEF 14A (7), PRE 14C (7), 10-K/A (6), DEF 14C (6), UPLOAD (6), CORRESP (5), CT ORDER (5), NT 10-K (5), 10-K405 (4), 10-Q/A (4), PRER14C (4), S-8 (3), POS AM (2), RW (2), S-8 POS (2), SC 13G (2), 10-K405/A (1), 10-KT (1), 15-12G (1), 424B3 (1), ARS (1), EFFECT (1), PRE 14A (1), S-1 (1), S-1/A (1), S-3 (1), SB-2 (1), SC 13E3 (1), SC 13E3/A (1)

  • Latest filingsAnnual report (10-K) Apr 11, 2023
    Quarterly report (10-Q) Nov 20, 2023
    Proxy statement (DEF 14A) Apr 30, 2002
    Latest 8-K (8-K) Dec 28, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
    SEC EDGAROther events
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
    SEC EDGAROther events
  31. 31
    SEC EDGAROther events
  32. 32
  33. 33
  34. 34